These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
157 related articles for article (PubMed ID: 1687206)
1. Taxol: a new and effective anti-cancer drug. Slichenmyer WJ; Von Hoff DD Anticancer Drugs; 1991 Dec; 2(6):519-30. PubMed ID: 1687206 [TBL] [Abstract][Full Text] [Related]
2. Taxol: an important new drug in the management of epithelial ovarian cancer. Markman M Yale J Biol Med; 1991; 64(6):583-90. PubMed ID: 1687343 [TBL] [Abstract][Full Text] [Related]
3. Phase I and pharmacodynamic study of taxol in refractory acute leukemias. Rowinsky EK; Burke PJ; Karp JE; Tucker RW; Ettinger DS; Donehower RC Cancer Res; 1989 Aug; 49(16):4640-7. PubMed ID: 2568175 [TBL] [Abstract][Full Text] [Related]
4. [Pharmacological action of paclitaxel]. Potemski P; Płuzańska A Pol Merkur Lekarski; 1999 Jan; 6(31):27-9. PubMed ID: 10344150 [TBL] [Abstract][Full Text] [Related]
5. Phase I trial of taxol given as a 3-hour infusion every 21 days. Kris MG; O'Connell JP; Gralla RJ; Wertheim MS; Parente RM; Schiff PB; Young CW Cancer Treat Rep; 1986 May; 70(5):605-7. PubMed ID: 2871928 [TBL] [Abstract][Full Text] [Related]
6. [Paclitaxel (Taxol)]. Hájek R Cas Lek Cesk; 1996 Jun; 135(12):393-6. PubMed ID: 8706079 [TBL] [Abstract][Full Text] [Related]
7. Phase I trial of taxol in patients with advanced cancer. Donehower RC; Rowinsky EK; Grochow LB; Longnecker SM; Ettinger DS Cancer Treat Rep; 1987 Dec; 71(12):1171-7. PubMed ID: 2891441 [TBL] [Abstract][Full Text] [Related]
8. New natural products in cancer chemotherapy. Slichenmyer WJ; Von Hoff DD J Clin Pharmacol; 1990 Sep; 30(9):770-88. PubMed ID: 1980498 [TBL] [Abstract][Full Text] [Related]
9. Paclitaxel: a new antimitotic chemotherapeutic agent. Gotaskie GE; Andreassi BF Cancer Pract; 1994; 2(1):27-33. PubMed ID: 7914453 [TBL] [Abstract][Full Text] [Related]
11. [Paclitaxel (taxol): a review of its antitumor activity and toxicity in clinical studies]. Yamazaki S; Sekine I; Saijo N Gan To Kagaku Ryoho; 1998 Mar; 25(4):605-15. PubMed ID: 9530372 [TBL] [Abstract][Full Text] [Related]
12. [Taxol and ovarian adenocarcinomas]. Marty M; Extra JM; Culine S; Rousseau F Pathol Biol (Paris); 1992 Nov; 39(9):834-5. PubMed ID: 1347165 [No Abstract] [Full Text] [Related]
13. Paclitaxel: a new antineoplastic agent for refractory ovarian cancer. Gregory RE; DeLisa AF Clin Pharm; 1993 Jun; 12(6):401-15. PubMed ID: 7691462 [TBL] [Abstract][Full Text] [Related]
14. [Taxol (paclitaxel), first molecule of a new class of cytotoxic agents: taxanes]. Chazard M; Pellae-Cosset B; Garet F; Soares JA; Lucidi B; Lavail Y; Lenaz L Bull Cancer; 1994 Mar; 81(3):173-81. PubMed ID: 7894125 [TBL] [Abstract][Full Text] [Related]
15. Phase I study of taxol administered as a short i.v. infusion daily for 5 days. Grem JL; Tutsch KD; Simon KJ; Alberti DB; Willson JK; Tormey DC; Swaminathan S; Trump DL Cancer Treat Rep; 1987 Dec; 71(12):1179-84. PubMed ID: 2891442 [TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of topotecan in the treatment of advanced ovarian carcinoma. ten Bokkel Huinink W; Carmichael J; Armstrong D; Gordon A; Malfetano J Semin Oncol; 1997 Feb; 24(1 Suppl 5):S5-19-S5-25. PubMed ID: 9122738 [TBL] [Abstract][Full Text] [Related]
17. Taxol as second-line treatment in patients with advanced ovarian cancer after platinum-based first-line chemotherapy. Mayerhofer K; Kucera E; Zeisler H; Speiser P; Reinthaller A; Sevelda P Gynecol Oncol; 1997 Jan; 64(1):109-13. PubMed ID: 8995557 [TBL] [Abstract][Full Text] [Related]
18. Role of paclitaxel in the treatment of breast cancer: the American Cooperative Group Experience. Sledge GW Semin Oncol; 1996 Feb; 23(1 Suppl 1):10-2. PubMed ID: 8629029 [TBL] [Abstract][Full Text] [Related]